Download PDF
Dtsch Med Wochenschr 2014; 139(49): 2494-2497
DOI: 10.1055/s-0034-1387406
Endokrinologie | Commentary
Diabetologie
© Georg Thieme Verlag KG Stuttgart · New York

Moderne medikamentöse Therapie des Typ-2-Diabetes

Modern medical treatment of type 2 diabetes
M. Hanefeld
1   GWT-TUD GmbH, Studienzentrum „Prof. Hanefeld“, Dresden
2   Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl-Gustav Carus, Dresden
,
S. R. Bornstein
2   Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl-Gustav Carus, Dresden
3   Paul-Langerhans-Institut für Diabetesforschung, Technische Universität Dresden
4   Center of Regenerative Therapies, Dresden
5   Department of Diabetes and Endocrinology, Divison of Diabetes and Nutrients, King’s College London, UK
,
A. Barthel
2   Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl-Gustav Carus, Dresden
6   Endokrinologikum Ruhr, Bochum
› Author Affiliations
Further Information

Publication History

Publication Date:
25 November 2014 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Typ-2-Diabetes - Arzneimitteltherapie - Leitlinien - Patienten-zentrierte Therapie

Keywords

type-2-diabetes mellitus - drug therapy - guidelines - patient centered treatment
 

  • Literatur

  • 1 Gerstein HC, Miller ME, Genuth S. ACCORD Study Group et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818-828
    CrossrefPubMedGoogle Scholar
  • 2 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes. –Langfassung, zuletzt geändert April 2014; http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_therapie/pdf/nvl-t2d-therapie-lang-3.pdf (letzter Zugriff 29. September 2014)
    Google Scholar
  • 3 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596
    CrossrefPubMedGoogle Scholar
  • 4 Kim HS, Shin JA, Lee SH et al. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. Diabetes Technol Ther 2013; 15: 810-816
    CrossrefPubMedGoogle Scholar
  • 5 Mathieu C, Hollander P, Miranda-Palma B et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013; 98: 1154-1162
    CrossrefPubMedGoogle Scholar
  • 6 McIntosh B, Cameron C, Singh SR et al. Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis. Open Med 2012; 6: e62-74
    PubMedGoogle Scholar
  • 7 Meier JJ, Nauck MA. Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia 2014; 57: 1320-1324
    CrossrefPubMedGoogle Scholar
  • 8 Musso G, Gambino R, Cassader M et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44: 375-393
    CrossrefPubMedGoogle Scholar
  • 9 Nauck MA, Del Prato S, Durán-García S et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab 2014; doi: 10.1111/dom.12327
    PubMedGoogle Scholar
  • 10 Nauck MA. A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care 2013; 36: 2126-2132
    CrossrefPubMedGoogle Scholar
  • 11 Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011; 124 (Suppl. 01) S3-18
    CrossrefPubMedGoogle Scholar
  • 12 Pozzilli P, Leslie RD, Chan J et al. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev 2010; 26: 239-244
    CrossrefPubMedGoogle Scholar
  • 13 Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-26
    CrossrefPubMedGoogle Scholar
  • 14 Selvin E, Steffes MW, Zhu H et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362: 800-811
    CrossrefPubMedGoogle Scholar
  • 15 White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335
    CrossrefPubMedGoogle Scholar